REmote SUpervision to Decrease HospitaLization RaTe. Unified and integrated platform for data collected from devices manufactured by different companies: Design and rationale of the RESULT study
Mateusz Tajstra, Adam Sokal, Arkadiusz Gwóźdź, Marcin Wilczek, Adam Gacek, Konrad Wojciechowski, Elżbieta Gadula-Gacek, Elżbieta Adamowicz-Czoch, Katarzyna Chłosta-Niepiekło, Krzysztof Milewski, Piotr Rozentryt, Zbigniew Kalarus, Mariusz Gąsior, Lech Poloński, Mateusz Tajstra, Adam Sokal, Arkadiusz Gwóźdź, Marcin Wilczek, Adam Gacek, Konrad Wojciechowski, Elżbieta Gadula-Gacek, Elżbieta Adamowicz-Czoch, Katarzyna Chłosta-Niepiekło, Krzysztof Milewski, Piotr Rozentryt, Zbigniew Kalarus, Mariusz Gąsior, Lech Poloński
Abstract
The number of patients with heart failure implantable cardiac electronic devices (CIEDs) is growing. Hospitalization rate in this group is very high and generates enormous costs. To avoid the need for hospital treatment, optimized monitoring and follow-up is crucial. Remote monitoring (RM) has been widely put into practice in the management of CIEDs but it may be difficult due to the presence of differences in systems provided by device manufacturers and loss of gathered data in case of device reimplantation. Additionally, conclusions derived from studies about usefulness of RM in clinical practice apply to devices coming only from a single company. An integrated monitoring platform allows for more comprehensive data analysis and interpretation. Therefore, the primary objective of Remote Supervision to Decrease Hospitalization Rate (RESULT) study is to evaluate the impact of RM on the clinical status of patients with ICDs or CRT-Ds using an integrated platform. Six hundred consecutive patients with ICDs or CRT-Ds implanted will be prospectively randomized to either a traditional or RM-based follow-up model. The primary clinical endpoint will be a composite of all-cause mortality or hospitalization for cardiovascular reasons within 12 months after randomization. The primary technical endpoint will be to construct and evaluate a unified and integrated platform for the data collected from RM devices manufactured by different companies. This manuscript describes the design and methodology of the prospective, randomized trial designed to determine whether remote monitoring using an integrated platform for different companies is safe, feasible, and efficacious (ClinicalTrials.gov Identifier: NCT02409225).
Keywords: RESULT study; heart failure; integrated platform; remote monitoring.
Conflict of interest statement
None declared.
© 2016 Wiley Periodicals, Inc.
Figures



Source: PubMed
Kommende kliniske studier
-
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Har ikke rekruttert ennåIkke-småcellet lungekreftKina
-
RenJi HospitalChanghai Hospital; First People's Hospital of Hangzhou; West China Hospital; Chengdu University of Traditional Chinese Medicine og andre samarbeidspartnereHar ikke rekruttert ennå
-
RenJi HospitalChanghai Hospital; First People's Hospital of Hangzhou; West China Hospital; Chengdu University of Traditional Chinese Medicine og andre samarbeidspartnereRekruttering
-
CSPC Megalith Biopharmaceutical Co.,Ltd.Har ikke rekruttert ennå
-
Foundation EndourologyThe International Alliance of UrolithiasisRekruttering
-
Istanbul Galata UniversityThe Scientific and Technological Research Council of TurkeyHar ikke rekruttert ennåSystemisk Lupus Erythematosus(SLE)Tyrkia (Türkiye)
-
Postgraduate Institute of Dental Sciences RohtakRekruttering
-
Prof Ibrahim JanahiHar ikke rekruttert ennåObesity-associated AsthmaQatar
-
Sohag UniversityHar ikke rekruttert ennåParkinsons sykdom
-
Greater Atlanta Integrative PediatricsRekrutteringAutismespektrumforstyrrelse | Autisme | ASD | Autismespektrumforstyrrelse (ASD)Forente stater
-
The General Hospital of Western Theater CommandHar ikke rekruttert ennåThrombocytopenic Purpura, Immune
-
Guangdong Hengrui Pharmaceutical Co., LtdHar ikke rekruttert ennåGeneralisert myasthenia gravisKina